Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update
Conclusions (2 of 2)
Most osteoporosis interventions have notable adverse effects that should be taken into account in decisionmaking.
Dosing frequency appears to affect adherence and persistence, with weekly doses having improved adherence over daily regimens.
Limited evidence suggests that treatment extended beyond 5 years can provide additional reductions in vertebral fracture risk (measured at 10 years). For nonvertebral fractures, post-hoc analysis found reduction in risk only for women who had osteoporosis or prevalent vertebral fractures at five years of treatment.
Monitoring BMD during therapy does not fully reflect treatment benefits, as patients with BMD losses during antiresorptive therapy may still experience reduced fracture risk.
Keywords: bone | low bone density | bone density | osteoporosis | fracture | osteopenia | skeletal | dose | bone mineral density | BMD | antifracture
- Newberry SJ, Crandall CC, Gellad WG, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update to the 2007 Report. Comparative Effectiveness Review No. 53 (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 12-EHC023-EF. Available at www.effectivehealthcare.ahrq.gov/reports/lbd.cfm.
Your slide tray is being processed.